ClinicalTrialsFinder
CompletedPhase 3ACTRN12605000232639

Dose Response Study of a Complementary Medicine Formulation in Primary Hypercholesterolaemia

Dose Response Studyto determine the efficacy and safety of a Complementary Medicine Formulation, in tablet form, for lowering lipid levels in primary Hypercholesterolaemia by comparing baseline levels of lipids with post treatment lipid levels.

Sponsor

Pathways

Enrollment

40 participants

Start Date

Oct 9, 2002

Study Type

Interventional

Conditions

Primary Hypercholesterolaemia

Summary

This study is a two arm open comparison of two different dosage regimes undertaken in a homogeneous population comparing baseline measurements with effects of treatment.

Eligibility

Sex: Both males and femalesMin Age: 18 Yearss

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying dose Response Study of a Complementary Medicine Formulation in Primary Hypercholesterolaemia. You may be eligible if you are adults aged 18 and older who lDL cholesterol 3.5 and 5.7mmol/L. People with individuals with triglyceride levels >4mmol/l, individuals with a total cholesterol level >10 mmol/l, individuals with clinically abnormal liver function tests at baseline (measured at visit 2) may not be able to participate. Participation may involve medical tests, study visits, and follow-up appointments.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Cynara scolymus: One arm took one tablet of the study medication twice a day (morning and evening with meals) and the other arm took two tablets twice a day (morning and evening with meals).

Cynara scolymus: One arm took one tablet of the study medication twice a day (morning and evening with meals) and the other arm took two tablets twice a day (morning and evening with meals).

Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12605000232639

Related Trials

A Study to Compare PK Characteristics and Safety Profiles Between AD-228B and AD-2284

NCT068840981 location